Key Highlights

  • Twist Bioscience closed up 15.65% at $115.01 on August 5, a fresh 52-week high.
  • The rally builds on fiscal third-quarter results reported August 3, in which revenue rose 23% year-over-year to $118.4 million, a 3.34% beat.
  • Management raised full-year fiscal 2026 revenue guidance to $456 million to $457 million, up from a prior range of $442 million to $447 million.
  • The company priced an upsized $300 million public stock offering to fund research and manufacturing capacity expansion.
  • The rally comes alongside broader healthcare sector strength and a record-setting rally across major indices this week.

What Happened

Twist Bioscience (NASDAQ:TWST) is a South San Francisco-based synthetic biology company founded in 2013 that has developed a proprietary silicon-based DNA synthesis platform, enabling high-throughput, cost-effective manufacturing of synthetic DNA at unprecedented precision and scale. The company offers a broad portfolio of products and services, including synthetic genes, oligo pools, NGS target enrichment tools, and antibody discovery solutions, serving over 3,800 customers globally.

Shares closed at a fresh 52-week high on August 5, extending momentum from Monday's fiscal third-quarter report and a raised full-year outlook. Revenue for the quarter rose 23% year-over-year to $118.4 million, a 3.34% beat versus consensus, marking the 14th consecutive quarter of sequential growth, with gross margin expanding to 52.8%, up 120 basis points.

Capital Raise Fuels Growth Investment

The company further built on that strength today by pricing an upsized $300 million public stock offering to fund research and development, manufacturing capacity expansion, and working capital, an announcement that appeared to reinforce rather than undermine investor confidence given the strong underlying growth trajectory. Management raised full-year fiscal 2026 revenue guidance to $456 million to $457 million, up from a prior range of $442 million to $447 million, expecting continued strong growth in both DNA Synthesis and NGS, and reaffirmed its commitment to adjusted EBITDA breakeven in fiscal Q4 and sustained profitability in fiscal 2027.

Company management highlighted continued competitive advantages including its semiconductor-based DNA synthesis platform, new complex genes product launch after 1,800 orders across 100-plus early customers, and manufacturing cost reductions of 60%, 70%, and 73% faster turnaround over three years, expanding total addressable market projected to reach $13 billion by 2030. The company ended the third quarter with $166.8 million in cash and short-term investments.

AI Drug Discovery as a Growth Driver

CEO and co-founder Emily Leproust reaffirmed confidence in exceeding triple-digit percentage order growth in fiscal 2026 and expects to repeat triple-digit percentage order growth in fiscal 2027, citing durable demand from existing and new customers, expansion into new modalities, and strong funnel visibility. AI-enabled drug discovery continues to mature into a durable growth engine as customers increasingly rely on AI models in therapeutic design.

Conclusion

Twist Bioscience's combination of raised guidance, a fourteenth consecutive quarter of growth, and a well-received capital raise suggests the market has grown increasingly confident in the company's path to sustained profitability entering fiscal 2027. With shares closing at fresh 52-week highs and broader healthcare sector strength providing an additional tailwind, today's advance reflects strong conviction in the durability of the company's growth trajectory.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.